Eagle Asset Management Inc. lifted its holdings in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 1.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,635,140 shares of the biotechnology company’s stock after acquiring an additional 30,688 shares during the quarter. Eagle Asset Management Inc. owned approximately 3.04% of Atara Biotherapeutics worth $23,088,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in the stock. Baupost Group LLC MA raised its holdings in shares of Atara Biotherapeutics by 9.7% during the second quarter. Baupost Group LLC MA now owns 7,000,000 shares of the biotechnology company’s stock valued at $140,770,000 after acquiring an additional 619,481 shares in the last quarter. BlackRock Inc. raised its holdings in Atara Biotherapeutics by 10.2% in the second quarter. BlackRock Inc. now owns 3,841,451 shares of the biotechnology company’s stock worth $77,252,000 after purchasing an additional 357,026 shares in the last quarter. Vanguard Group Inc. raised its holdings in Atara Biotherapeutics by 4.6% in the second quarter. Vanguard Group Inc. now owns 3,011,596 shares of the biotechnology company’s stock worth $60,563,000 after purchasing an additional 132,282 shares in the last quarter. Maverick Capital Ltd. raised its holdings in Atara Biotherapeutics by 156.4% in the second quarter. Maverick Capital Ltd. now owns 2,232,476 shares of the biotechnology company’s stock worth $44,895,000 after purchasing an additional 1,361,712 shares in the last quarter. Finally, Morgan Stanley raised its holdings in Atara Biotherapeutics by 55.8% in the second quarter. Morgan Stanley now owns 1,997,538 shares of the biotechnology company’s stock worth $40,171,000 after purchasing an additional 715,077 shares in the last quarter. Institutional investors own 91.98% of the company’s stock.
A number of research firms have issued reports on ATRA. JPMorgan Chase & Co. downgraded Atara Biotherapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $43.00 to $22.00 in a report on Friday. Stifel Nicolaus reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Friday, October 25th. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 8th. BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 29th. Finally, Jefferies Financial Group cut Atara Biotherapeutics from a “buy” rating to a “hold” rating and cut their target price for the stock from $32.00 to $15.00 in a research note on Monday, September 16th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $28.89.
In other news, insider Joe Newell sold 3,500 shares of the firm’s stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $13.51, for a total value of $47,285.00. Following the transaction, the insider now owns 57,998 shares of the company’s stock, valued at $783,552.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.00% of the stock is owned by company insiders.
Shares of NASDAQ ATRA traded down $0.12 during trading on Friday, reaching $13.40. The company had a trading volume of 545,300 shares, compared to its average volume of 677,343. The business’s 50-day moving average is $13.16 and its 200 day moving average is $18.16. The company has a quick ratio of 7.80, a current ratio of 7.80 and a debt-to-equity ratio of 0.06. Atara Biotherapeutics Inc has a 12-month low of $10.38 and a 12-month high of $43.94. The stock has a market cap of $679.50 million, a PE ratio of -2.54 and a beta of 2.04.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($1.31) EPS for the quarter, topping the consensus estimate of ($1.40) by $0.09. On average, analysts anticipate that Atara Biotherapeutics Inc will post -5.71 earnings per share for the current year.
Atara Biotherapeutics Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Read More: What are the reasons investors use put options?
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.